Example: stock market
Investor Update

Investor Update

Back to document page

Furthermore, the FDA granted two additional Breakthrough Therapy Designations (BTD): for Venclexta/Venclyxto combination therapy for the treatment of adult patients with myelodysplastic syndromes, a rare form of blood cancer. This marks the sixth BTD for Venclexta/Venclyxto.

  Breakthrough

Download Investor Update


Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Advertisement

Related search queries